Search Within

Center for Pancreatic Cancer Research

Formats
  1. Journal Article (5063)
  2. Meeting Abstract (2483)
  3. Book Section (225)
  4. Review (221)
  5. Editorial (135)
  6. Conference Paper (75)
  7. Correspondence (48)
  8. Research Letter (43)
  9. Miscellaneous (41)
  10. Guidelines (38)
  11. Book Whole (20)
Groups
  1. Department of Medicine (3945)
  2. Solid Tumor Oncology Division (3243)
  3. Surgery (3170)
  4. GSK Faculty (2916)
  5. Epidemiology and Biostatistics (2526)
  6. Gastrointestinal Oncology Service (2298)

More Groups

People
  1. Mithat Gonen (1036)
  2. William Jarnagin (913)
  3. Eileen O'Reilly (795)
  4. Michael D'Angelica (789)
  5. T Peter Kingham (622)
  6. David Kelsen (538)

More People

Years
  1. 2025 (293)
  2. 2024 (497)
  3. 2023 (523)
  4. 2022 (602)
  5. 2021 (555)
  6. 2020 (562)

More Years

Publications
  1. Journal of Clinical Oncology (927)
  2. Annals of Surgical Oncology (397)
  3. Cancer Research (226)
  4. International Journal of Radiation Oncology, Biology, Physics (219)
  5. Laboratory Investigation (209)
  6. Modern Pathology (191)

More Publications

Publishers
  1. American Society of Clinical Oncology (1003)
  2. Springer (842)
  3. Elsevier Inc. (757)
  4. Nature Publishing Group (633)
  5. American Association for Cancer Research (551)
  6. Elsevier Science, Inc. (510)

More Publishers

Results (8392)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation
    Meeting Abstract

    Yu, K. H.; Weekes, C. D.; Chen, Y. B. A.; Glazier, J. A.; Glazier, A.; Dahi, P.; Giralt, S.; O'Reilly, E. M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Furuse, J.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Lee, H. J.; Bhattacharya, P. P.; Moran, D. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial
    Meeting Abstract

    Halfdanarson, T. R.; Capdevila, J.; Halperin, D. M.; Herrmann, K.; Kong, G.; Leyden, S.; Mailman, J.; Reidy-Lagunes, D.; Srirajaskanthan, R.; Erdö, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo-Cid, R.; Chandana, S. R.; De La Fouchardiere, C.; Dean, Andrew P.; Kiss, I.; Lee, W.; Goetze, T. O.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC)
    Meeting Abstract

    Keane, F.; Schoenfeld, J. D.; Crowley, F.; O'Connor, C. A.; White, C.; Schwartz, C.; Brenner, R.; Larsen, M.; Park, W.; Varghese, A. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC)
    Meeting Abstract

    Lyman, J. P.; Cabanski, C. R.; Maddock, S.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Rahma, O. E.; Fisher, G. A.; Gabriel, P. E.; Doucette, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in advanced pancreatic neuroendocrine neoplasms (PanNENs)
    Meeting Abstract

    Cowzer, D.; Shah, R. H.; Punn, S.; Fiedler, L.; DeMore, A.; Chou, J. F.; Capanu, M.; Berger, M. F.; Reidy-Lagunes, D.; Raj, N. P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO)
    Meeting Abstract

    Keane, F.; Balogun, F.; O'Connor, C.; Crowley, F.; Chan, A.; Cowzer, D.; Chou, J. F.; Park, W.; Varghese, A. M.; Yu, K. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer
    Meeting Abstract

    Reyngold, M.; Wei, A.; O'Reilly, E. M.; D'Angelica, M. I.; Drebin, J. A.; Soares, K.; Kingham, T. P.; Balachandran, V. P.; Varghese, A. M.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genetic heterogeneity of intrahepatic cholangiocarcinoma: Implications for outcome
    Meeting Abstract

    Song, Y.; Boerner, T.; Drill, E. N.; Shin, P.; Cercek, A.; Kemeny, N. E.; Abou-Alfa, G. K.; Iacobuzio-Donahue, C. A.; Schultz, N.; Walch, H. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save